Dusigitumab
Dusigitumab
Dusigitumab (pronounced as doo-si-gi-tu-mab) is a monoclonal antibody designed for the treatment of various cancer types. It is a type of immunotherapy that works by stimulating the body's immune system to attack cancer cells.
Etymology
The name "Dusigitumab" is derived from the International Nonproprietary Names (INN), where "Dusi" is a prefix used for drugs that target the T-cell receptor, "gi" stands for immunoglobulin (a type of protein), "tu" stands for tumor, and "mab" is a suffix for monoclonal antibodies.
Mechanism of Action
Dusigitumab works by binding to a specific protein found on the surface of cancer cells. This binding triggers the immune system to attack and destroy the cancer cells. The specific protein that Dusigitumab targets is known as the T-cell receptor, which plays a crucial role in the immune system's ability to recognize and destroy cancer cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
- T-cell receptor: A protein on the surface of T cells, a type of white blood cell, that recognizes and binds to specific antigens.
See Also
External links
- Medical encyclopedia article on Dusigitumab
- Wikipedia's article - Dusigitumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski